Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Phase 2

Completed

• Conditions: Psoriatic Arthritis
• Interventions: Drug: SUNPG18_07 I (Tildrakizumab 200 mg); Drug: SUNPG18_07 II (Tildrakizumab 100 mg)

• Registration Number: NCT03552276
• Lead Sponsor: Sun Pharmaceutical Industries Limited

Brief Summary

A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab

Detailed Description

Subjects have rolled over from parent study, i.e., CLR_16_23, into the long-term extension study CLR_18_07.

The study has been open label post 1 year completion.

Study Timeline

• Study First Submitted: 2018-05-04
• Study First Submitted QC: 2018-06-08
• Study First Posted: 2018-06-11
• Study Start: 2018-07-11
• Primary Completion: 2023-09-18
• Study Completion: 2023-09-18
• Results First Submitted: 2024-09-17
• Status Verified: 2024-10
• Results First Submitted QC: 2024-10-30
• Last Update Submitted: 2024-10-30
• Results First Posted: 2024-11-21
• Last Update Posted: 2024-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 281

Inclusion Criteria

Subjects may be included in the study if they meet all of the following criteria:

1. Subject has provided written informed consent for this long-term extension study.
2. Subjects with PsA who met the inclusion criteria of the parent study and completed the parent study treatment period (e.g., up to Week 48 for the parent Phase 2 study, with return for the EoT assessment at Week 52).
3. No concomitant use of both leflunomide and methotrexate,
4. No history of active tuberculosis (TB) or symptoms of TB.

Exclusion Criteria

Subjects should be excluded from the study if they meet any of the following criteria:

1. New onset during the parent study of arthritic conditions other than the subject's original condition.
2. Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo-progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon entering the study and through 16 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 16 weeks following final administration of IMP.
3. Female is pregnant or breastfeeding, or planning to become pregnant or initiate breastfeeding while enrolled in the study or up to 16 weeks after the last dose of IMP.
4. Subject has previously been enrolled in this long-term extension study.
5. Any condition that in the opinion of the Investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for the subject.
6. Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease (e.g., renal failure, heart failure, hypertension, liver disease, diabetes, or anemia) that, in the opinion of the Investigator, could cause continued treatment to be detrimental to the subject.
7. Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus during the parent study.
8. Subjects with a history of alcohol or drug abuse during the parent study.
9. Subject has a need for use of a live vaccine within 10 weeks of final anticipated dose of IMP for the long-term extension study.
10. Concomitant use of prohibited medications or use of commercially available or investigational biologic therapies (other than tildrakizumab) for PsO and/or PsA
11. Subjects who have been placed in an institution on official or judicial orders.
12. Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest may arise.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
SUNPG18_07 q4 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose	SUNPG18_07 I (Tildrakizumab 200 mg)	Tildrakizumab 200 mg q4 weeks switched to tildrakizumab 100 mg q12 weeks
SUNPG18_07 q4 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose	SUNPG18_07 II (Tildrakizumab 100 mg)	Tildrakizumab 200 mg q4 weeks switched to tildrakizumab 100 mg q12 weeks
SUNPG18_07 q12 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose	SUNPG18_07 I (Tildrakizumab 200 mg)	Tildrakizumab 200 mg q12 weeks switched to tildrakizumab 100 mg q12 weeks
SUNPG18_07 q4 weeks, high dose	SUNPG18_07 I (Tildrakizumab 200 mg)	Tildrakizumab 200 mg q4 Weeks
SUNPG18_07 q12 weeks, high dose	SUNPG18_07 I (Tildrakizumab 200 mg)	Tildrakizumab 200 mg q12 Weeks
SUNPG18_07 q12 weeks, low dose	SUNPG18_07 II (Tildrakizumab 100 mg)	Tildrakizumab 100 mg q12 Weeks
SUNPG18_07 q12 Weeks, High Dose to SUNPG18_07 q12 Weeks, Low Dose	SUNPG18_07 II (Tildrakizumab 100 mg)	Tildrakizumab 200 mg q12 weeks switched to tildrakizumab 100 mg q12 weeks

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events	upto week 208	Please refer to Adverse event section for more information

Trial Locations

Locations (66)

Site 25; 🇺🇸 Glendale, Arizona, United States

Site 16; 🇺🇸 Phoenix, Arizona, United States

Site 14; 🇺🇸 Denver, Colorado, United States

Site 27; 🇺🇸 Wichita, Kansas, United States

Site 23; 🇺🇸 Lexington, Kentucky, United States

Site 20; 🇺🇸 Monroe, Louisiana, United States

Site 26; 🇺🇸 Lebanon, New Hampshire, United States

Site 24; 🇺🇸 Salisbury, North Carolina, United States

Site 19; 🇺🇸 Cincinnati, Ohio, United States

Site 17; 🇺🇸 Middleburg Heights, Ohio, United States

Scroll for more (56 remaining)